Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.13-0.22 (-2.35%)
At close: 04:00PM EST
9.13 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close9.35
Open9.31
Bid9.10 x 800
Ask9.32 x 1000
Day's Range9.02 - 9.36
52 Week Range4.98 - 12.69
Volume562,365
Avg. Volume589,344
Market Cap1.158B
Beta (5Y Monthly)-0.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BELLUS Health Inc.
    Daily – Vickers Top Insider Picks for 11/29/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    14 hours agoArgus Research
View more
  • Business Wire

    BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

    LAVAL, Quebec, November 14, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitivity indications, today reported its financial and operating results for the third quarter ended September 30, 2022.

  • Business Wire

    BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

    LAVAL, Quebec, November 10, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.

  • Business Wire

    BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

    LAVAL, Quebec, October 10, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022.

Advertisement
Advertisement